Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 222, Issue 9, Pages 1478-1487Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiz672
Keywords
immunogenicity; Japanese encephalitis vaccine; Jenvac; SA 14-14-2
Categories
Funding
- BBIL [CTRI/2014/02/004386, CTRI/2016/05/006909]
Ask authors/readers for more resources
Background. This study reports immunogenicity, safety, and interchangeability of a single-dose, inactivated, Vero-cell derived, JENVAC to the live-attenuated SA 14-14-2 vaccine in healthy children. Methods. This phase 4, multicenter, open-label, randomized, control trial enrolled 360 children who were equally randomized to receive a single dose of either JENVAC or SA 14-14-2. Children were followed at various time points, until 2 years (day 720) postvaccination, upon which a subset from each group was divided and allocated to a receive a booster dose or the other vaccine. Results. At all time points, immunological measures were statistically higher in the JENVAC group. In the interchangeability study, children receiving 2 doses of JENVAC reported significantly higher response compared with 2 doses of SA 14-14-2. No difference in adverse events was observed. These corroborate with excellent seroprotection after the first dose of an earlier JENVAC study. Conclusions. A single-dose vaccination with JENVAC induces protective titers that persist up to 1 year. We report appreciable interchangeability between both vaccines, with JENVAC/JENVAC combination exhibiting the highest immune response. JENVAC is now licensed as a single-dose Japanese encephalitis vaccine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available